Table 1.
Patient demographics and anaemia-related characteristics (full analysis set)
| Parameter | Non-DD patients | DD patients |
|---|---|---|
| (n = 11 370) | (n = 3045) | |
| Age (years), median (IQR) | 73 (64–80) | 70 (58–78) |
| Sex (male), n (%) | 7164 (63) | 2052 (67) |
| eGFR (mL/min/1.73 m2), median (IQR) | 25 (17–33) | – |
| CKD stage, n (%) | ||
| Stage 3b | 3722 (33) | – |
| Stage 4 | 5520 (49) | – |
| Stage 5 | 2128 (19) | – |
| Dialysis type, n (%) | ||
| PD | – | 708 (23) |
| HD | – | 2337 (77) |
| Dialysis vintage (years), median (IQR) | – | 2.3 (1.0–4.4) |
| Comorbidities, n (%) | ||
| Cancer (previous 3 years) | 1669 (15) | 463 (15) |
| Cerebrovascular disease | 1180 (10) | 337 (11) |
| Diabetes mellitus | 3309 (29) | 1087 (36) |
| Heart failure | 1345 (12) | 382 (13) |
| Myocardial infarction | 1006 (9) | 313 (10) |
| Peripheral vascular disease | 1306 (12) | 451 (15) |
| hs-CRP (mg/L), median (IQR) | 5 (2–9) | 5 (3–13) |
| >5 mg/L, n (%)a | 2905 (33) | 1441 (50) |
| Anaemia, n (%)b | 6792 (60) | 2844 (93) |
| Hb (g/dL), mean (SD) | 12.3 (1.63) | 11.4 (1.34) |
| ESA users, n (%) | 2692 (24) | 2491 (82) |
| Iron medication users, n (%) | 2359 (21) | 1880 (62) |
| Oral | 1662 (15) | 97 (3) |
| IV | 697 (6) | 1783 (59) |
| Concomitant medications, n (%) | ||
| ACEi/ARB | 6487 (57) | 1093 (36) |
| β-blockers | 6643 (58) | 1814 (60) |
| Statins | 5761 (51) | 1170 (38) |
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
a
Percentage of patients with hs-CRP >5 mg/mL in those with a recorded level.
b
Included patients with Hb levels <13 g/dL (males) or <12 g/dL (females) and those treated with ESAs.